Effect of low dose gamma-butyrolactone therapy on forebrain neuronal ischemia in the unrestrained, awake rat.
Low dose gamma-butyrolactone (GBL) therapy alters the natural history of experimental forebrain ischemia in the awake rat. After 30 minutes of four-vessel ischemia, repeated hydrogen cerebral blood flow determinations in awake rats over 72 hours revealed that low dose GBL therapy prevented the development of regional cerebral hyperemia and later the prolonged cerebral hypoperfusion that was experienced by the nontreated controls. Moreover, the low dose GBL-treated group had significantly less neuronal tissue loss than that in comparable brain regions of the nontreated controls. Before the stroke studies, GBL dose-response experiments performed on normal rats indicated that high dose GBL therapy produced seizures, systemic hypertension, metabolic acidosis, hyperthermia, and death.
D015107:4-Butyrolactone / Q000627:therapeutic use*; D000818:Animals; D001929:Brain Edema / Q000188:drug therapy; D002545:Brain Ischemia / Q000188:drug therapy*; D002421:Caudate Nucleus / Q000098:blood supply; D002544:Cerebral Infarction / Q000188:drug therapy; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005625:Frontal Lobe / Q000098:blood supply; D005663:Furans / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D014715:Vertebrobasilar Insufficiency / Q000188:drug therapy
D005663:Furans; D015107:4-Butyrolactone